Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas

Executive Summary

There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.

Advertisement

Related Content

Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA
Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area
Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019
Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race
Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019
J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room
Top Financings: 2018 Was A Remarkable Year For Biopharma Fundraising
IPO Update: Returns Run Red For Most Biopharma Firms That Went Public In The US Last Year
Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?
UK's Nightstar NASDAQ Listing Backs British Biotech Build-Up Strategy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124876

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel